TABLE 2.

Example LOT determination differences between the proposed rules and other (Hess) rules.

Patient	Duration of regimen (days)	Regimen agent(s)	Proposed LOT	Hess LOT
Patient A	0–150	Erlotinib	1	1
	151–242	Osimertinib	2	2
	243–438	Bevacizumab, Carboplatin, Pemetrexed	3	3
	439–674	Pemetrexed	3	3
	675–702	Bevacizumab, Pemetrexed	4	3
	703–849	Pemetrexed	4	3
	881‐ongoing	Bevacizumab, Erlotinib	5	3
Patient B	0–630	Bevacizumab, Erlotinib	1	1
	632–1036	Osimertinib	2	2
	1038–1091	Osimertinib, Crizotinib	3	2
Patient C	0	Bevacizumab, Carboplatin, Pemetrexed	1	1
	30–800	Erlotinib	2	2
	802–904	Bevacizumab, Carboplatin, Pemetrexed	3	3
	905–1010	Bevacizumab, Pemetrexed	3	3
	1205–1849	Osimertinib	4	4
	1851–2035	Osimertinib, Gefitinib	5	4